youtube_live
Q2 2026 earnings • released • EPS beat +1.08% • Revenue beat +1.36%
See resultschevron_right
ABBV:NYSE
AbbVie Common Stock
$250.94
arrow_downward
-2.51%(-6.47) 1D
$251.62
arrow_upward
+0.27% (+0.68)bedtimeAfter hours
Closed: Jul 31, 4:03:25 PM GMT-4 · USD
search
All symbols
No data
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABBV...
Open
$252.54
High
$255.52
Low
$247.00
Mkt. cap
443.36B
Avg. vol.
8.20M
Volume
7.26M
Dividend
2.76%
Quarterly dividend
$1.73
Ex-dividend date
Jul 15, 2026
P/E ratio
123.84
52-wk high
$267.47
52-wk low
$189.78
EPS
$2.03
Beta
0.30
Shares outstanding
1.77B
No. of employees
57K
Open
$252.54
High
$255.52
Low
$247.00
Mkt. cap
443.36B
Avg. vol.
8.20M
Volume
7.26M
Dividend
2.76%
Quarterly dividend
$1.73
Ex-dividend date
Jul 15, 2026
P/E ratio
123.84
52-wk high
$267.47
52-wk low
$189.78
EPS
$2.03
Beta
0.30
Shares outstanding
1.77B
No. of employees
57K
News stories
From sources across the web
MarketBeat
·
12 hours ago
AbbVie Quietly Solved Its Biggest Problem—Now What?
Yahoo Finance
·
2 days ago
Why AbbVie Stock Slumped Today
MarketWatch
·
2 days ago
AbbVie Inc. stock underperforms Friday when compared to competitors
Yahoo Finance
·
2 days ago
ABBV Beats on Q2 Earnings & Sales, Cuts '26 EPS View, Stock Down
Profile
AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues.
The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. The name "AbbVie" is derived from a combination of "Abbott", the name of its former parent company, with "vie", intended as a reference to a Latin root meaning 'life'. Wikipedia
About AbbVie Common Stock
CEORobert A. Michael
Employees57K
FoundedApr 10, 2012
HeadquartersNorth Chicago, Illinois, United States
SectorBiotechnology
Websiteabbvie.com
Analyst ratings
Based on 22 analysts giving stock ratings to ABBV in the past 3 months
Strong buy
Buy
18
Hold
4
Sell
0
12-month forecast
Based on 22 Wall Street analysts offering 12 month price targets for ABBV in the last 3 months.
Highest
Current $250.94
$300.00 (+19.55%)
Average
$272.57 (+8.62%)
Lowest
$225.00 (-10.34%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Matt Phipps William Blair | Buy | Reiterated | - | - | 07/31/2026 |
Steve Scala TD Cowen | Buy | Maintained | $280.00 | +11.6% | 07/31/2026 |
Jason Gerberry Bank of America Securities | Buy | Maintained | $276.00 | +10% | 07/31/2026 |
Emily Field Barclays | Buy | Maintained | $300.00 | +19.6% | 07/29/2026 |
David Amsellem Piper Sandler | Buy | Reiterated | $298.00 | +18.8% | 07/28/2026 |
Courtney Breen Bernstein | Hold | Maintained | $225.00 | -10.3% | 07/22/2026 |
Gary Nachman Canaccord Genuity | Buy | Reiterated | $282.00 | +12.4% | 07/22/2026 |
Asad Haider Goldman Sachs | Hold | Maintained | $244.00 | -2.8% | 07/21/2026 |
Geoff Meacham Citi | Hold | Maintained | $260.00 | +3.6% | 07/16/2026 |
Michael Yee UBS | Hold | Reiterated | $260.00 | +3.6% | 07/13/2026 |
Evan Seigerman BMO Capital | Buy | Maintained | $300.00 | +19.6% | 07/13/2026 |
Michael Harvey RBC Capital | Buy | Reiterated | $280.00 | +11.6% | 07/10/2026 |
Trung Huynh RBC Capital | Buy | Reiterated | $280.00 | +11.6% | 07/10/2026 |
Tim Anderson Bank of America Securities | Buy | Maintained | $276.00 | +10% | 07/10/2026 |
Mohit Bansal Wells Fargo | Buy | Reiterated | $295.00 | +17.6% | 07/10/2026 |
Chris Schott J.P. Morgan | Buy | Reiterated | $280.00 | +11.6% | 07/09/2026 |
Vamil Divan Guggenheim | Buy | Reiterated | $261.00 | +4% | 07/08/2026 |
Louise Chen Scotiabank | Buy | Maintained | $280.00 | +11.6% | 07/07/2026 |
Rajesh Kumar HSBC | Buy | Maintained | $300.00 | +19.6% | 07/06/2026 |
Carter Gould Cantor Fitzgerald | Buy | Maintained | $265.00 | +5.6% | 07/06/2026 |
Terence Flynn Morgan Stanley | Buy | Maintained | $278.00 | +10.8% | 06/22/2026 |
Tyler Van Buren TD Cowen | Buy | Reiterated | $280.00 | +11.6% | 06/23/2026 |
Nicholas Lorusso TD Cowen | Buy | Reiterated | $280.00 | +11.6% | 06/23/2026 |
Gavin Clark-Gartner Evercore ISI | Buy | Reiterated | $235.00 | -6.4% | 05/15/2026 |
Jasper Hellweg Argus Research | Buy | Reiterated | $250.00 | -0.4% | 05/13/2026 |
Luisa Hector Berenberg Bank | Buy | Maintained | $275.00 | +9.6% | 05/08/2026 |
Unknown Analyst Canaccord Genuity | Buy | Initiated | $262.00 | +4.4% | 04/20/2026 |
Hans Engel Erste Group | Hold | Maintained | - | - | 04/01/2026 |
Nico Chen DBS | Hold | Maintained | $230.00 | -8.3% | 02/25/2026 |
Last report
Jul 31, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$3.65 / $3.61
+1.08%beat
arrow_upward
Revenue / Est. (USD)
16.99B / 16.76B
+1.36%beat
arrow_upward
Fiscal Q2 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 15.78B | 16.62B | 15.00B | 16.99B |
Cost of goods sold | 4.46B | 4.55B | 4.22B | - |
Cost of revenue | 4.46B | 4.55B | 4.22B | - |
Research and development expenses | 2.29B | 2.58B | 2.47B | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 3.43B | 3.82B | 3.49B | - |
Operating expense | 5.72B | 6.40B | 5.96B | - |
Total operating expenses | 10.18B | 10.95B | 10.18B | - |
Operating income | 5.60B | 5.67B | 4.82B | - |
Other non operating income | 199.00M | 120.00M | -21.00M | - |
EBT including unusual items | 714.00M | 2.67B | 1.04B | - |
EBT excluding unusual items | 5.11B | 5.12B | 4.17B | - |
Income tax expense | 526.00M | 853.00M | 342.00M | - |
Effective tax rate | 73.67% | 31.97% | 32.92% | - |
Other operating expenses | - | - | - | - |
Net income | 186.00M | 1.82B | 695.00M | - |
Net profit margin | 1.18% | 10.93% | 4.63% | 21.27% |
Earnings per share | 1.86 | 2.71 | 2.65 | 3.65 |
Interest and investment income | 72.00M | 59.00M | 72.00M | - |
Interest expense | -739.00M | -714.00M | -717.00M | - |
Net interest expenses | -667.00M | -655.00M | -645.00M | - |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 7.66B | 7.66B | 6.76B | - |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
AI content may include mistakes. Learn more